Published in Eur Urol on July 18, 2005
Bone metastases in germ cell tumor patients. J Cancer Res Clin Oncol (2012) 0.82
A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Ann Oncol (2005) 3.53
European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol (2004) 2.65
Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer (2004) 1.93
The growing teratoma syndrome: results of therapy and long-term follow-up of 33 patients. Eur J Cancer (2000) 1.74
A randomized trial of prednisolone in patients with severe alcoholic hepatitis. N Engl J Med (1992) 1.71
Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol (1997) 1.67
Carcinoma of an unknown primary site: a chemotherapy strategy based on histological differentiation--results of a prospective study. Ann Oncol (2001) 1.44
[Recommendations for the treatment of prostate cancer in the elderly man: A study by the oncology committee of the French association of urology]. Prog Urol (2009) 1.40
High failure rate of carboplatin-etoposide combination in good risk non-seminomatous germ cell tumours. Eur J Cancer (1993) 1.39
Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. Ann Oncol (1995) 1.32
Relating genotype and phenotype in breast cancer: an analysis of the prognostic significance of amplification at eight different genes or loci and of p53 mutations. Cancer Res (2000) 1.30
Five-year change in statistical designs of phase II trials published in leading cancer journals. Eur J Cancer (2004) 1.24
Desmoplastic small round cell tumors: results of a four-drug chemotherapy regimen in five adult patients. Cancer (1996) 1.23
The human homologue of the putative proto-oncogene Spi-1: characterization and expression in tumors. Oncogene (1990) 1.21
Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy--results from an international study group. J Clin Oncol (2001) 1.20
Prognostic variables for response and outcome in patients with extragonadal germ-cell tumors. Ann Oncol (2002) 1.09
Stage I non-seminomatous germ-cell tumours of the testis: identification of a subgroup of patients with a very low risk of relapse. Eur J Cancer (2001) 1.06
Reversible posterior leukoencephalopathy syndrome after carboplatin therapy. Ann Oncol (2006) 1.05
The risk of thrombo-embolic events is increased in patients with germ-cell tumours and can be predicted by serum lactate dehydrogenase and body surface area. Br J Cancer (2005) 1.05
Summary of the Standards, Options and Recommendations for the management of patients with carcinoma of unknown primary site (2002). Br J Cancer (2003) 1.05
Primary mediastinal nonseminomatous germ cell tumors: results of modern therapy including cisplatin-based chemotherapy. J Clin Oncol (1998) 1.04
Adult granulosa-cell tumor of the ovary: a retrospective study of 45 cases. Int J Gynecol Cancer (1997) 1.03
Increased expression of class III beta-tubulin in castration-resistant human prostate cancer. Br J Cancer (2009) 1.00
Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients. Cancer Res (1994) 0.99
Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy? Br J Cancer (2007) 0.98
Phase II study of oxaliplatin and fluorouracil in taxane- and anthracycline-pretreated breast cancer patients. J Clin Oncol (2002) 0.95
Squamous cell carcinoma of the penis: multivariate analysis of prognostic factors and natural history in monocentric study with a conservative policy. Ann Oncol (1997) 0.95
Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer. Br J Cancer (2004) 0.95
Prompt resolution of acute disseminated intravascular coagulation with docetaxel and cisplatin in hormone refractory prostate cancer. J Urol (2002) 0.94
Treatment outcome of patients with brain metastases from malignant germ cell tumors. Cancer (1999) 0.94
The growing teratoma syndrome: a woman with nonseminomatous germ cell tumor of the ovary. Gynecol Oncol (1993) 0.93
Small cell cancer of the bladder: pathology, diagnosis, treatment and prognosis. Bull Cancer (2009) 0.91
Survival and reproductive function of 52 women treated with surgery and bleomycin, etoposide, cisplatin (BEP) chemotherapy for ovarian yolk sac tumor. Ann Oncol (2008) 0.90
Multimodality treatment of patients with liver metastases from germ cell tumors: the role of surgery. Cancer (2001) 0.90
Quantification of docetaxel and its main metabolites in human plasma by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom (2005) 0.90
Free hCG-beta subunit as tumour marker in urothelial cancer. Lancet (1993) 0.88
Initial management of primary mediastinal seminoma: radiotherapy or cisplatin-based chemotherapy? Eur J Cancer (1998) 0.87
Patient preference for either the EORTC QLQ-C30 or the FACIT Quality Of Life (QOL) measures: a study performed in patients suffering from carcinoma of an unknown primary site (CUP). Eur J Cancer (2004) 0.86
Oxaliplatin in non-seminomatous germ-cell tumors. Ann Oncol (2004) 0.86
Bayesian estimate of vinorelbine pharmacokinetic parameters in elderly patients with advanced metastatic cancer. Clin Cancer Res (2000) 0.85
[The French clinical trials ongoing (GETUG and AFU) on urothelial carcinomas, kidney and prostate cancers]. Prog Urol (2010) 0.85
[Malignant tumors of the adrenal: contribution to the repository CCAFU INCa]. Prog Urol (2010) 0.84
A phase I and pharmacokinetic study of melphalan using a 24-hour continuous infusion in patients with advanced malignancies. Clin Cancer Res (2000) 0.83
Adult Wilms' tumour: review of 22 cases. Eur J Cancer (1994) 0.82
Salvage chemotherapy in non-dysgerminomatous germ cell tumours of the ovary. Eur J Cancer (1995) 0.82
[Histological features and principles of treating testicle tumors in the elderly subject]. Prog Urol (2009) 0.81
Early adjuvant intraportal chemotherapy after curative hepatectomy for colorectal liver metastases--a pilot study. Eur J Surg Oncol (1987) 0.81
[Anaplastic thyroid carcinoma: aggressive radical resection and cervical reconstruction. A case report]. Ann Chir (2006) 0.81
Phase II study of oxaliplatin versus oxaliplatin combined with infusional 5-fluorouracil in hormone refractory metastatic prostate cancer patients. Ann Oncol (2003) 0.81
Simultaneous determination of dexamethasone and 6 beta-hydroxydexamethasone in urine using solid-phase extraction and liquid chromatography: applications to in vivo measurement of cytochrome P450 3A4 activity. J Chromatogr B Analyt Technol Biomed Life Sci (2004) 0.80
[Recommendations Onco-Urology 2010: Malignancies of the penis]. Prog Urol (2010) 0.80
Recombinant interferon-alpha efficacy in relapsed adult nephroblastoma: a case report. J Urol (1994) 0.79
Paratesticular rhabdomyosarcoma in adult patients: 16-year experience at Institut Gustave-Roussy. Ann Oncol (1993) 0.79
[The role of chemotherapy in the management of bladder cancer]. Prog Urol (2011) 0.79
[First line indications for hormonal therapy in prostate cancer]. Prog Urol (2009) 0.79
[Treatment of lymph nodes in epidermoid carcinoma of the penis: review of literature by the Committee of Cancerology of the French Association of Urology-External Genital Organs Group (CCAFU-OGE)]. Prog Urol (2009) 0.79
[Recommendations Onco-Urology 2010: Germ cell testicular tumors.]. Prog Urol (2010) 0.79
Pharmacokinetics of high-dose intravenous melphalan in patients undergoing peripheral blood hematopoietic progenitor-cell transplantation. Anticancer Res (1997) 0.79
[Mesenteric venous infarction and protein C deficiency]. Gastroenterol Clin Biol (1989) 0.78
Phase II trial of ifosfamide, fluorouracil, and folinic acid (FIFO regimen) in relapsed and refractory urothelial cancer. Cancer Invest (1995) 0.78
[Desmoplastic small round cell tumors in adults: a new entity]. Bull Cancer (1995) 0.78
[Efficacy of the combination of 5 fluorouracil, adriamycin and cisplatin (FAP protocol) in the treatment of metastatic cylindroma. Apropos of a case with review of the literature]. Bull Cancer (1994) 0.78
[Prognostic factors in renal cell carcinoma]. Bull Cancer (2009) 0.78
Population pharmacokinetics of topotecan: intraindividual variability in total drug. Cancer Chemother Pharmacol (2000) 0.78
[Primary, highly malignant B-cell lymphoma of the prostate. Apropos of a case and review of the literature]. Bull Cancer (1994) 0.78
Intensive and timely chemotherapy, the key of success in testicular cancer. Crit Rev Oncol Hematol (2001) 0.78
Experience with bleomycin, etoposide, cisplatin (BEP) and alternating cisplatin, cyclophosphamide, doxorubicin (CISCA(II))/vinblastine, bleomycin (VB(IV)) regimens of chemotherapy in poor-risk nonseminomatous germ cell tumors. Am J Clin Oncol (1997) 0.78
Cisplatin alone or combined with gemcitabine in carcinomas of unknown primary: results of the randomised GEFCAPI 02 trial. Eur J Cancer (2012) 0.78
Phase II study of all-trans retinoic acid administered intermittently for hormone refractory prostate cancer. J Urol (1999) 0.78
Penile cancer chemotherapy: twelve years' experience at Institut Gustave-Roussy. Urology (1993) 0.78
Salivary and plasma pharmacokinetics of topotecan in patients with metastatic epithelial ovarian cancer. Eur J Cancer (2001) 0.77
[Primary mediastinal non-seminomatous germ-cell tumors: from clinics to biology]. Bull Cancer (1997) 0.77
Association between germ cell tumours, large numbers of naevi, atypical naevi and melanoma. Melanoma Res (2001) 0.77
Hepatocellular carcinoma during hormonotherapy for prostatic cancer. Am J Clin Oncol (1994) 0.77
Effects of impaired renal function on the pharmacokinetics and toxicity of i.v. ZD9331, a novel non-polyglutamated thymidylate synthase inhibitor, in adult patients with solid tumors. Anticancer Drugs (2002) 0.77
Cisplatin-based chemotherapy in advanced seminoma: the Institut Gustave Roussy experience. Eur J Cancer (1998) 0.76
New cytotoxic drugs in clinical development. Nouv Rev Fr Hematol (1991) 0.76
Cytotoxicity of iridals, triterpenoids from Iris, on human tumor cell lines A2780 and K562. Planta Med (2001) 0.76
Acute tumor lysis syndrome in poor-risk germ cell tumors: does it exist? Support Care Cancer (1994) 0.76
Combining gemcitabine, cisplatin, and ifosfamide (GIP) is active in patients with relapsed metastatic germ-cell tumors (GCT): a prospective multicenter GETUG phase II trial. Ann Oncol (2014) 0.76